StockNews.AI
PEPG
StockNews.AI
63 days

PEPG LAWSUIT ALERT: Levi & Korsinsky Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

1. PepGen Inc. facing a class action for alleged securities fraud. 2. Claims include false effectiveness of PGN-EDO51 and unsafe CONNECT2 study. 3. Investors could recover losses without upfront costs. 4. Investors have until August 2025 to act on the lawsuit. 5. Reputational damage may impact PepGen's future funding opportunities.

5m saved
Insight
Article

FAQ

Why Very Bearish?

Class action lawsuits often lead to significant stock price declines. Similar cases have historically resulted in sustained periods of stock volatility.

How important is it?

The ongoing lawsuit poses severe risks to PEPG's market perception and operational continuity.

Why Long Term?

The reputational damage from the lawsuit may harm investor confidence long after the case concludes, affecting future business.

Related Companies

VRTXVRTXBAYRYSAGE

NEW YORK, June 17, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=153282&wire=4

CONTACT:

PEPG investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that:

  1. (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe;
  2. (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval;
  3. (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and
  4. (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.

WHAT'S NEXT?

If you suffered a loss in PepGen Inc. during the relevant time frame, you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

Related News